UTSA researchers explore little-known, deadly fungal infections

April 10, 2018

A new study by Althea Campuzano, Ph.D. a student at The University of Texas at San Antonio, and Floyd Wormley, Jr., Professor of Biology and Senior Associate Dean for Research and Graduate Studies, sheds light on little-known fungal infections caused by the fungus Cryptococcus. There are currently no vaccines available for any fungal infection, which can be extremely deadly to patients under treatment for diseases like HIV, AIDS and cancer. Campuzano and Wormley suggest that more research is needed to develop an effective solution to these infections.

"Cryptococcus is a type of fungus that all humans are frequently exposed to without much effect," Campuzano said. "People with healthy immune systems might be infected but may feel no symptoms. It is often cleared or kept in check without people even knowing they've encountered it."

However, a person whose immune system is weakened by illness could face serious complications from being infected by Cryptococcus because the immune system is less able to respond appropriately to the infection when it's weakened. As a result, the body's innate cells, which normally destroy pathogens, allow the fungal infection to spread to the brain, which can lead to meningitis.

"Most people who are infected with fungal meningitis find they have a stiff neck or a headache. The danger is that if it's left untreated, they could be dead within weeks," Wormley said.

People undergoing treatments that could weaken their immune systems are most susceptible to fungal infections. Patients about to undergo organ transplants, for example, take medication to suppress their immune systems to keep their bodies from rejecting the new organ. AIDS, HIV and cancer patients also experience weakened immunity as a result of the illness or their treatments.

"People who have HIV or AIDS often have to be on anti-fungal treatments for the rest of their lives," Wormley said. "That long treatment can lead to the development of fungi that are resistant to the anti-fungal therapy. Also, it's a very trying thing to treat for a long period of time."

In their study, Wormley and Campuzano highlight all current knowledge of the receptors on innate cells, which are responsible for recognizing fungal pathogens and present an argument for more research in the effort of a vaccine or immunotherapy treatment for Cryptococcus.

"One of the biggest challenges we're facing is that no vaccine currently exists for any fungal infection," Campuzano said. "It's not for lack of trying, but part of the problem is that the immune system has such a hard time distinguishing between a human cell and a fungal cell."

Campuzano is working toward that goal by taking a closer look at CARD9, a protein that regulates receptors on innate cells. She and Wormley are interested in how CARD9 regulates the ability of the body to recognize fungi and whether they could manipulate it to trigger an immune response.

"We need more research involved with fungal pathogens in general," she said. "We're advocating for it so that we can work on a vaccine. A lot of people know about the dangers in bacteria and viruses, but this just isn't on their radar at all. We're going to change that."
UTSA is ranked among the top four universities in the nation under 50 years old, according to Times Higher Education.

University of Texas at San Antonio

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.